These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 31915169)

  • 21. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.
    Sarri G; Hernandez LG
    J Comp Eff Res; 2024 Sep; 13(9):e240061. PubMed ID: 39132748
    [No Abstract]   [Full Text] [Related]  

  • 23. Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau CY; Rawson NSB
    Curr Oncol; 2024 Sep; 31(9):5599-5607. PubMed ID: 39330042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making.
    Tadrous M; Aves T; Fahim C; Riad J; Mittmann N; Prieto-Alhambra D; Rivera DR; Chan K; Lix LM; Kent S; Dawoud D; Guertin JR; McDonald JT; Round J; Klarenbach S; Stanojevic S; De Vera MA; Strumpf E; Platt RW; Husein F; Lambert L; Hayes KN
    J Clin Epidemiol; 2024 Dec; 176():111545. PubMed ID: 39322123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.
    Jaksa A; Wu J; Jónsson P; Eichler HG; Vititoe S; Gatto NM
    J Comp Eff Res; 2021 Jun; 10(9):711-731. PubMed ID: 33928789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence, values, and funding decisions in Canadian cancer systems.
    Peacock SJ; Regier DA; Raymakers AJN; Chan KKW
    Healthc Manage Forum; 2019 Nov; 32(6):293-298. PubMed ID: 31645144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.
    Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G
    Ther Innov Regul Sci; 2024 Nov; 58(6):1042-1052. PubMed ID: 39060838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
    Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
    Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
    Phillips CM; Parmar A; Guo H; Schwartz D; Isaranuwatchai W; Beca J; Dai W; Arias J; Gavura S; Chan KKW
    Cancer; 2020 Apr; 126(8):1717-1726. PubMed ID: 31913522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
    Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Healthcare Claims Data to Generate Real-World Evidence on Patients With Drug-Resistant Epilepsy: Practical Considerations for Research.
    Stamas N; Vincent T; Evans K; Li Q; Danielson V; Lassagne R; Berger A
    J Health Econ Outcomes Res; 2024; 11(1):57-66. PubMed ID: 38425708
    [No Abstract]   [Full Text] [Related]  

  • 34. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.
    Jenei K; Peacock S; Burgess M; Mitton C
    Curr Oncol; 2021 Jul; 28(4):2708-2719. PubMed ID: 34287280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.
    Oehrlein EM; Graff JS; Harris J; Perfetto EM
    Patient; 2019 Aug; 12(4):375-381. PubMed ID: 30666526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes.
    Anderson P; Higgins V; Courcy J; Doslikova K; Davis VA; Karavali M; Piercy J
    Curr Med Res Opin; 2023 Dec; 39(12):1707-1715. PubMed ID: 37933204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
    Lau C; Jamali F; Loebenberg R
    J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
    Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
    Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.